Bioactivity:

ERK-IN-1 �is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.�The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), KRAS-mut

CAS nr:

1715025-32-3

Purity:

98%

Molecular Weight:

578,42

SMILES:

O=C(N[C@@H](C1=CC(F)=CC(Br)=C1)CNC)C2=CC=C(C3=NC([C@@H]4C[C@H](F)[C@@H](O)CC4)=CN=C3N)C=C2F

Formula:

C26H27BrF3N5O2

Pathway:

MAPK,MAPK

Target:

Raf,ERK